Interview with Devaney Baccarin, VP & General Manager, Astellas Pharma…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
Address: Avenida das Nações Unidas, 14.171, Rochaverá Corporate Towers, Torre Marble – 3º andar, Cj. 302,Brazil
Tel: (55 11) 3027-4500
Web: http://www.astellasfarma.com.br/
In July 2009, Astellas Pharma Brazil (AFB) was created due to remarkable growth of the economy in the sector of health care. In April 2010, the Brazilian subsidiary started to promote and distribute products directly that were licensed to other companies.
In Brazil, specifically, Astellas is focused on three areas encompassed in the Astellas Group, Dermatology, Urology and Infectious Diseases. These are the foundations for growth and recognition of Astellas in the Brazilian pharmaceutical market.
Astellas Brazil focuses on becoming the leader in the Brazilian pharmaceutical industry, supports the company’s business philosophy, a VISION 2015, which seeks to become a ‘world leader in the category.’
Omnic®, Omnic OCAS®, Vesicare, Mycamine
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
See our Cookie Privacy Policy Here